Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/44380
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of Gastroesophageal reflux disease |
Author: | Omari, T. Davidson, G. Bondarov, P. Naucler, E. Nilsson, C. Lundborg, P. |
Citation: | Journal of Pediatric Gastroenterology and Nutrition, 2007; 45(5):530-537 |
Publisher: | Lippincott Williams & Wilkins |
Issue Date: | 2007 |
ISSN: | 0277-2116 1536-4801 |
Statement of Responsibility: | Taher Omari, Geoffrey Davidson, Patrik Bondarov, Emma Naucler, Catarina Nilsson and Per Lundborg |
Abstract: | <h4>Objectives</h4>To evaluate the pharmacokinetics and acid-suppressive effects of esomeprazole in infants with gastroesophageal reflux disease (GERD).<h4>Patients and methods</h4>In this single-blind, randomized, parallel-group study, 50 infants 1 to 24 months old with symptoms of GERD, and >or=5% of time with intraesophageal pH <4 during 24-hour dual pH monitoring, received oral esomeprazole 0.25 mg/kg (n = 26) or 1 mg/kg (n = 24) once daily for 1 week. Intraesophageal and intragastric pH were recorded at 1 week, and blood samples were taken for pharmacokinetic analysis.<h4>Results</h4>At baseline, mean percentages of time with intragastric pH >4 and intraesophageal pH <4 were 30.5% and 11.6%, respectively, in the esomeprazole 0.25 mg/kg group and 28.6% and 12.5% in the esomeprazole 1 mg/kg group. After 1 week of treatment, times with intragastric pH >4 were 47.9% and 69.3% in the esomeprazole 0.25 mg/kg and 1 mg/kg groups, respectively (P < 0.001 vs baseline), and times with intraesophageal pH <4 were 8.4% (P < 0.05 vs baseline) and 5.5% (P < 0.001 vs. baseline), respectively. The mean number of acid reflux episodes of >5 minutes duration decreased from 6 at baseline to 3 and 2 with esomeprazole 0.25 mg/kg and 1 mg/kg, respectively. The geometric mean AUC0-t of esomeprazole were 0.24 and 1.79 micromol x h/L for the 0.25 mg/kg and 1 mg/kg dosages of esomeprazole, respectively. Both esomeprazole dosages were well tolerated.<h4>Conclusions</h4>Oral treatment with esomeprazole 0.25 mg/kg and 1 mg/kg was well tolerated and provided dose-related acid suppression, dose-related exposure to esomeprazole, and decreased esophageal acid exposure in infants 1-24 months old with GERD. |
Keywords: | Humans Gastroesophageal Reflux Anti-Ulcer Agents Treatment Outcome Administration, Oral Severity of Illness Index Area Under Curve Single-Blind Method Dose-Response Relationship, Drug Hydrogen-Ion Concentration Time Factors Child, Preschool Infant Infant, Newborn Australia Esomeprazole |
Rights: | © 2007 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition |
DOI: | 10.1097/MPG.0b013e31812e012f |
Published version: | http://journals.lww.com/jpgn/pages/articleviewer.aspx?year=2007&issue=11000&article=00003&type=abstract |
Appears in Collections: | Aurora harvest 6 Paediatrics publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.